Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.
Clover Health Investments, Corp. (Nasdaq: CLOV) is a physician enablement technology company and Medicare Advantage insurer whose activities generate frequent news across healthcare, technology, and capital markets. The company focuses on Medicare Advantage PPO and HMO plans in several states and uses its Clover Assistant platform to support clinical decision-making and chronic disease management for people on Medicare.
News about Clover Health often centers on membership growth and plan performance in Medicare Advantage, including updates on enrollment during the Annual Enrollment Period, changes in plan offerings, and the design of affordable, high-choice PPO products. Company announcements also highlight clinical quality achievements, such as HEDIS performance and CMS Star Ratings for its PPO and HMO plans, which influence future payment years and are important to investors and healthcare partners.
Because Clover Health combines insurance operations with a technology platform, its news flow includes technology and data-driven care developments. This can involve new research and whitepapers from its subsidiary Counterpart Health on the impact of Counterpart Assistant, evidence on earlier diagnosis and reduced hospitalizations for chronic diseases, and platform enhancements such as ambient scribing, natural language chat, and enterprise-level tools for value-based care.
Investors and industry observers can also expect earnings releases, financial guidance updates, and SEC-related communications, including Form 8-K filings tied to quarterly results, responses to shareholder questions, and commentary on CMS rate and Star Rating changes. In addition, Clover Health periodically announces participation in major healthcare investor conferences and changes in its board of directors or governance structure.
This news page aggregates these developments in one place, allowing readers to follow Clover Health’s progress in Medicare Advantage, its technology initiatives through Clover Assistant and Counterpart Health, and its ongoing financial and regulatory disclosures over time.
Clover Health (Nasdaq: CLOV) reported a 53% year-over-year increase in Medicare Advantage PPO membership for the 2026 plan year, entering 2026 with ~153,000 members. The company said >95% AEP retention and that >97% of members are in its flagship PPO, which it ranks #1 nationally on core HEDIS metrics. Clover expects to achieve its first full-year GAAP net income profitability in 2026, citing improving cohort economics, SG&A leverage, a 4.0 Star payment impact, and a favorable 2026 CMS rate update.
Counterpart Health (CLOV) reported 2025 highlights showing scaled clinical impact from its AI physician‑enablement platform, Counterpart Assistant (CA). Key outcomes include a >450% YoY increase in live third‑party customer clinicians, an approximate 1,500 basis point MCR differential for returning Clover members with CA PCPs, and the PPO Medicare Advantage plan achieving the #1 HEDIS score nationwide for a second year.
Retrospective analyses found earlier COPD diagnosis (new members 75% more likely in year one), higher outpatient pulmonology use (+18%), lower all‑cause hospitalizations (CHF −18%; COPD −15%), reduced 30‑day readmissions (CHF −25%; COPD −18%), and 70–89% higher diagnosis rates in high ADI neighborhoods. Product expansions included integrated ambient scribing, natural language chat, proactive visit summaries, and broader enterprise capabilities.
Clover Health (Nasdaq: CLOV) said its CEO Andrew Toy will present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026 at 11:15 a.m. ET.
A live webcast and a replay of the presentation and Q&A will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Clover Health (Nasdaq: CLOV) announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 Citi Global Healthcare Conference on Thursday, December 4, 2025 at 11:15 a.m. ET.
A live webcast and replay will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Clover Health (NASDAQ: CLOV) reported Q3 2025 results: Medicare Advantage membership 109,226 (+35% YoY) and Total revenues $496.7M (+50% YoY). Q3 profitability metrics: GAAP net loss $24.4M, Adjusted EBITDA $2.1M, and Adjusted Net income $1.7M. Year-to-date Adjusted EBITDA is $45.0M and Adjusted Net income is $43.7M. Cash and investments totaled $395.9M (down 25.5% YoY). Q3 Insurance BER rose to 93.5% from 82.8% a year earlier; Normalized Insurance BER was 92.4%.
The company raised full‑year 2025 guidance: Avg. MA membership 106k–108k, Insurance revenue $1.85B–$1.88B, Adjusted SG&A $325M–$335M, and Adjusted EBITDA $15M–$30M. Management cited cohort economics, retention, and a favorable 2026 CMS environment as drivers toward improved profitability.
Clover Health (Nasdaq: CLOV) announced that Chelsea Clinton will step down from its Board of Directors effective October 31, 2025 after more than eight years of service, having joined in early 2017.
During her tenure the company grew from serving 30,000 members as a private firm to serving more than 100,000 seniors as a public company across multiple states. Clinton served on the Talent & Compensation Committee and the Nominating and Corporate Governance Committee. Company leaders thanked her for her guidance and emphasized continued commitment to a diverse, experienced Board to support Clover’s mission and growth.
Counterpart Health (Nasdaq: CLOV) released a whitepaper (Oct 30, 2025) showing its Counterpart Assistant (CA) tech helped primary care teams in high Area Deprivation Index neighborhoods detect chronic disease earlier and reduce hospital use.
Key results: diagnosis rates were higher for diabetes (+75%), CKD (+89%), CHF (+89%) and COPD (+70%); CKD detected at average Stage 2 vs 3A; diabetes A1C averaged 6.8% vs 7.1%; inpatient hospitalizations fell -7.6% to -21.2% and 30-day readmissions fell -11.5% to -20.8% across four diseases.
Clover Health (Nasdaq: CLOV) announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 UBS Global Healthcare Conference on Tuesday, November 11, 2025 at 11:00 a.m. Eastern Time.
A live webcast and replay will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.
Clover Health (Nasdaq: CLOV) announced its 2026 Medicare Advantage portfolio, preserving a comprehensive PPO lineup with $0 to low monthly premiums and Part B givebacks as Annual Enrollment Period opens Oct 15–Dec 7, 2025. The company says 100% of members will have stable or improved 2026 benefits and plans will be accessible to 5.2 million Medicare-eligible beneficiaries across 203 counties in 5 states. Clover credits its AI-powered Clover Assistant with earlier interventions—doctors start diabetes oral meds ~3 years earlier and diagnose CKD ~1.5 years earlier—and reports 32% YoY MA member growth.
Counterpart Health (CLOV) said its AI-driven HEDIS flywheel again powered Clover Health Medicare Advantage plans to top-tier results and made the platform available to third-party partners on Oct 14, 2025. Clover was the #1 performing PPO for HEDIS clinical quality measures among plans over 2,000 members and the only PPO in the Top 10. The flywheel combines point-of-care Counterpart Assistant prompts, real-time ingestion from 100+ data sources, NLP/LLM abstraction, and AI-augmented documentation closure to raise quality and reduce administrative burden.
Counterpart cites improved benchmark rates for screenings and diabetic eye exams and plans to scale the platform to more partners.
FAQ
What is the current stock price of Clover Health Investments (CLOV)?
What is the market cap of Clover Health Investments (CLOV)?
